Roche puts down $75M to sign on as new partner for Ionis' dry AMD drug, following Huntington's deal
Ionis is teaming up with Roche again, this time to develop an antisense drug for dry AMD with an upfront payment of $75 million to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
